CORGARD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Corgard, and when can generic versions of Corgard launch?
Corgard is a drug marketed by Uswm and is included in one NDA.
The generic ingredient in CORGARD is nadolol. There are five drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the nadolol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Corgard
A generic version of CORGARD was approved as nadolol by RISING on October 31st, 1993.
Summary for CORGARD
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,544 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CORGARD |
| What excipients (inactive ingredients) are in CORGARD? | CORGARD excipients list |
| DailyMed Link: | CORGARD at DailyMed |
Recent Clinical Trials for CORGARD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| BioHealthonomics Inc. | Phase 2 |
| AgoneX Biopharmaceuticals, Inc. | Phase 2 |
| Invion, Inc. | Phase 1/Phase 2 |
Pharmacology for CORGARD
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for CORGARD
US Patents and Regulatory Information for CORGARD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-005 | Oct 28, 1986 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CORGARD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-004 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-003 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Uswm | CORGARD | nadolol | TABLET;ORAL | 018063-005 | Oct 28, 1986 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CORGARD
See the table below for patents covering CORGARD around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | 163633 | ⤷ Try a Trial | |
| Switzerland | 550770 | PROCEDE DE PREPARATION DE NOUVEAUX COMPOSES 2,3-CISTETRAHYDRONAPHTYLOXY-AMINOPROPANOL. | ⤷ Try a Trial |
| United Kingdom | 1358722 | ⤷ Try a Trial | |
| Japan | S54157550 | MANUFACTURE OF TETRAHYDRONAPHTHALENE TRIOLS | ⤷ Try a Trial |
| Japan | S5747981 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
